1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Lactate Dehydrogenase

Lactate Dehydrogenase

LDH

Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+. LDH is comprised of two major subunits, LDH-A and LDH-B, which can assemble into five different isoenzymes (LDH1, LDH2, LDH3, LDH4, and LDH5).

LDH-A is also known as the M subunit as it is predominantly found in skeletal muscle, and LDH-B is also known as the H subunit as it is predominantly found in the heart. LDH-A is a vital metabolic enzyme that is associated with cancer development, invasion, and metastasis. LDH-A is also the key player of the Warburg effect. LDH-A has been reported to correlate with clinicopathologic characteristics and survival outcome of multiple cancers. The inhibition of LDH-A has an anti-proliferative effect on primary breast tumors. LDH-B is a crucial glycolytic enzyme that catalyses conversion of lactate and NAD+ to pyruvate, NADH and H+. LDHB plays an important role in autophagy in cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N7393
    Isomalt
    ≥98.0%
    Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes.
    Isomalt
  • HY-156683
    CHK-336
    Inhibitor
    CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM) that inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria.
    CHK-336
  • HY-115875
    LDHA-IN-5
    Inhibitor
    LDHA-IN-5 is a novel, potent, dual GO/LDHA inhibitor for primary hyperoxaluria.
    LDHA-IN-5
  • HY-154865
    Anticancer agent 121
    Inhibitor
    Anticancer agent 121, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research.
    Anticancer agent 121
  • HY-156442
    MEDS433
    Inhibitor
    MEDS433 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 1.2 nM. MEDS433 exerts a potent antiviral activity against RSV-A and RSV-B in the one-digit nanomolar range. MEDS433 induces the expression of antiviral proteins encoded by interferon stimulated genes (ISGs) able to reduce RSV replication.
    MEDS433
  • HY-W040073S
    Nifurtimox-d4
    Inhibitor
    Nifurtimox-d4 is deuterium labeled Nifurtimox. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
    Nifurtimox-d<sub>4</sub>
  • HY-154866
    Anticancer agent 122
    Inhibitor
    Anticancer agent 122, an inhibitor of human lactate dehydrogenase A enzyme (hLDHA), has good anticancer activities and can be used for anticancer research.
    Anticancer agent 122
  • HY-135648
    PfDHODH-IN-1
    Inhibitor 99.85%
    PfDHODH-IN-1 is an analogue of the active metabolite of Leflunomide. PfDHODH-IN-1 is a Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor. PfDHODH-IN-1 has antimalarial activity.
    PfDHODH-IN-1
  • HY-150753
    RS6212
    Inhibitor
    RS6212 is a specific LDH (lactate dehydrogenase) inhibitor with an IC50 value of 12.03 μM . RS6212 inhibits tumor growth and exhibits potent anticancer activity in multiple cancer cell lines.
    RS6212
Cat. No. Product Name / Synonyms Application Reactivity